Evidence-Based Care

Tapering Off Psychiatric Medications

Carefully supervised, gradual reduction of psychiatric medications, guided by current evidence, with close monitoring and support.

A Thoughtful, Evidence-Based Approach

There are many valid reasons to consider reducing or stopping psychiatric medications—from sustained stability and readiness to try life without medication, to side effects, pregnancy planning, or preference for non-pharmacological approaches. Whatever your reason, we believe medication decisions should be made collaboratively, informed by evidence, and carried out as safely as possible. We support thoughtful, evidence-based deprescribing, and a lower stable dose can be just as valid a goal as stopping entirely.

Research shows that abrupt discontinuation can lead to withdrawal (discontinuation) symptoms, symptom recurrence, or other complications. NICE guidance (2022) and the Maudsley Deprescribing Guidelines (2024) recommend gradual tapering with progressively smaller reductions as the dose gets lower.

Withdrawal can be dangerous. Stopping some medications suddenly, especially benzodiazepines, sleep medications such as Z-drugs, and some anticonvulsants, or stopping alcohol after heavy use, can cause seizures, confusion or hallucinations and can be life-threatening. Never stop or reduce a medication on your own. Severe withdrawal may need hospital or other medically supervised care. If you have seizures, confusion, hallucinations or thoughts of suicide, call 911 or call or text 988.

Research on Deprescribing

Horowitz and Taylor (2019), writing in The Lancet Psychiatry, showed that serotonin-transporter occupancy rises steeply at low antidepressant doses. As a result, equal-sized dose cuts have increasingly large effects toward the end of a taper. This pharmacology supports hyperbolic tapering, where reductions get smaller as the dose gets lower, an approach now reflected in NICE guidance and the Maudsley Deprescribing Guidelines. Trials comparing tapering methods directly are still limited.

In May 2026, the U.S. Department of Health and Human Services announced an initiative on psychiatric prescribing that includes informed consent, shared decision-making and deprescribing, with formal federal guidance on tapering to follow. Whatever the policy climate, we approach every decision about continuing or reducing a medication individually, weighing your benefits and risks.

Our Evidence-Based Tapering Process

  • Comprehensive Assessment
    Review of medication history, current stability, previous discontinuation attempts, and reasons for wanting to taper. Assessment of relapse risk factors.
  • Individualized Tapering Plan
    A personalized plan, built and adjusted with your psychiatrist, in which reductions generally become smaller and slower at lower doses, where discontinuation symptoms are more likely. The pace follows how you feel, not a fixed calendar.
  • Close Monitoring
    Regular check-ins using validated symptom scales (DESS, PHQ-9, GAD-7) to distinguish between discontinuation symptoms and symptom recurrence. Pace adjustments as needed.
  • Supportive Strategies
    Evidence-based psychotherapy, lifestyle interventions, and coping strategies to support the transition and maintain stability.

Medications We Help Taper

Antidepressants (SSRIs, SNRIs, TCAs, MAOIs)
Benzodiazepines and Z-drugs (tapered slowly, often over many months, in line with the 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering)
Mood Stabilizers such as lithium (higher relapse risk; always tapered gradually under close monitoring)
Antipsychotics (relapse risk requires careful, individualized planning)
Other Sleep Medications
ADHD Medications

Physical dependence is an expected effect of long-term benzodiazepine use and is not the same as addiction. If you have ever had a withdrawal seizure or withdrawal delirium, please tell us, because some tapers need a more closely supervised setting.

Important Safety Information

Never stop or reduce psychiatric medications without medical supervision. Abrupt discontinuation can cause serious withdrawal symptoms, seizures (with some medications), or rapid symptom recurrence. Withdrawal from benzodiazepines or alcohol can be life-threatening. Our goal is to help you reach your goals as safely as possible.

Tapering Research

  • ~1 in 6 people stopping an antidepressant have symptoms attributable to stopping; about 1 in 35 have severe symptoms. Most are mild and short-lived (Henssler 2024; Kalfas 2025)
  • Gradual slower, smaller reductions near the end of a taper are recommended by NICE and the Maudsley Deprescribing Guidelines
  • Months to years tapers vary by medication and person, and finding a lower stable dose is also a successful outcome

The Concierge Difference

Your dedicated psychiatrist knows your complete medication history and guides you through each step. Frequent check-ins and the kind of close monitoring that careful tapering requires, which is difficult to provide in brief, infrequent appointments.

Understanding Hyperbolic Tapering

Equal-sized dose cuts have a small effect on the brain at higher doses but an increasingly large effect toward the end of a taper. Hyperbolic tapering is designed around this pharmacology.

Equal-Step (Linear) Tapering

Reducing by the same amount at every step may feel manageable early on, but the final steps can produce a much larger change in the medication's effect on the brain.

Final steps can be the hardest

Hyperbolic Tapering

Hyperbolic tapering means making dose reductions progressively smaller as the dose gets lower, because the last part of the dose of many medications has the largest effect on the brain. In practice, this often means the final stages of a taper take the longest.

Designed to keep each step more even

The right steps, intervals and formulations differ by medication and by person, so your plan is built and adjusted with your psychiatrist. It is not a fixed schedule, and this page is not a guide to tapering on your own.

When to Consider Tapering

Appropriate Candidates

  • Sustained stability (typically 6-12+ months)
  • Resolution of original symptoms
  • Strong support system in place
  • Access to psychotherapy if needed
  • Pregnancy planning (we review the risks and benefits of continuing, switching or tapering, ideally before conception)
  • Troublesome side effects

Proceed with Caution

  • History of severe or recurrent episodes
  • Previous difficult discontinuation attempts
  • Current major life stressors
  • Limited support system
  • History of suicidality
  • Bipolar disorder or a history of psychosis
  • History of withdrawal seizures or delirium

What We Monitor

  • Discontinuation symptoms (DESS scale)
  • Mood changes (PHQ-9, GAD-7)
  • Sleep quality
  • Functional status
  • Warning signs of relapse

References & Further Reading

  1. Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 6(6), 538-546.
  2. National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE guideline NG222). https://www.nice.org.uk/guidance/ng222
  3. Horowitz, M. A., & Taylor, D. (2024). The Maudsley Deprescribing Guidelines. Wiley.
  4. Brunner, E., et al. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering. Journal of General Internal Medicine, 40(12), 2814-2859. https://doi.org/10.1007/s11606-025-09499-2
  5. Henssler, J., et al. (2024). The Lancet Psychiatry, 11(7), 526-535.
  6. Kalfas, M., et al. (2025). JAMA Psychiatry, 82(9), 896-904.
  7. Substance Abuse and Mental Health Services Administration. (2026, May 4). HHS launches MAHA action plan to curb psychiatric overprescribing [Press release]. https://www.samhsa.gov/newsroom/press-announcements/20260504/hhs-launches-maha-action-plan-curb-psychiatric-overprescribing
  8. Taylor, D., Barnes, T. R. E., & Young, A. H. (2021). The Maudsley Prescribing Guidelines in Psychiatry (14th ed.). Wiley-Blackwell.
  9. Cosci, F., & Chouinard, G. (2020). Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics, 89(5), 283-306.
  10. Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological Psychiatry, 44(2), 77-87.
Important Notice: The information on this page is for educational purposes only and does not constitute medical advice. Medication changes should only be made under the supervision of a qualified healthcare provider. Never stop or reduce psychiatric medications without medical guidance. Individual tapering plans must be tailored to your specific situation, medication history, and risk factors.

Ready to Explore Your Options?

If you're considering reducing or stopping your medications, we're here to help you do it as safely as possible. Request a private consultation to discuss your goals with your dedicated psychiatrist.

Call (610) 632-7781 Request a Private Consultation

Email is not monitored 24/7. Please do not send medical details by email. In a crisis, call or text 988, call 911, or go to the nearest emergency room.